Picture Bionordic Nordic Life Science Days 2018 Stockholm 600x60px
Document › Details

Kiadis Pharma N.V.. (3/12/18). "Press Release: Kiadis Pharma Launches a Private Placement of Approximately 2.6 Million New Shares [Not for United States, Australia, Canada, Japan, South Africa or any other Jurisdiction in which Unlawful]". Amsterdam.

Organisations Organisation Kiadis Pharma N.V. (Euronext: KDS)
  Group Kiadis (Group)
  Organisation 2 Jefferies International Ltd.
  Group Leucadia (Group)
Products Product ATIR101™ (Kiadis)
  Product 2 investment banking
Index term Index term Kiadis–SEVERAL: investment, 201803 private placement €23.4m w 2.6m new shares €9/share to institutional investors
Person Person Hård, Karl (Kiadis 201709– Head IR + Communications before Redx Pharma 201610– Head of IR + CorpComm before AstraZeneca)

Record changed: 2018-03-31


Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px

More documents for Kiadis (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2018 Boston September 600x60px

» top